Exclusion criteria: <br>1. Received prior treatment with a taxane.<br>2. Chronic or current active infectious disease requiring systemic antibiotics, antifungal, or antiviral treatment.<br>3. Known active central nervous system (CNS) metastases. Subjects with CNS metastases who have completed a course of therapy would be eligible for the study provided they are clinically stable for at least 1 month prior to study entry, defined as:<br>a. No evidence of new or enlarging CNS metastasis or new neurological symptoms<br>attributable to CNS metastases.<br>b. Asymptomatic and off all corticosteroids and anticonvulsants for at least 1 month prior to study entry.<br>4. Peripheral neuropathy = Grade 3.<br>5. Clinically significant cardiac disease including unstable angina, acute myocardial infarction within 6 months from Day 1 of study drug administration, New York Heart Association Class III or IV congestive heart failure, and arrhythmia requiring therapy.<br>6. Adequate renal, hepatic, and bone marrow function demonstrated by protocol-specified laboratory parameters at the screening visit. If the subject has any of the following, they are excluded:<br>a. ANC < 1.5 × 109/L.<br>b. Platelet count < 100 × 109/L.<br>c. Hemoglobin < 9 g/L (transfusion are permitted to achieve baseline hemoglobin level.)<br>d. Alanine aminotransferase (ALT)/aspartate aminotransferase (AST) > 2.5 × the upper limit of normal (ULN); or > 5 × ULN in the presence of liver metastases.<br>e. Alkaline phosphatase (ALP) > 2.5 × ULN.<br>f. Subjects with ALT or AST elevation > ULN and ALP > ULN.<br>g. Total bilirubin > ULN.<br>h. Creatinine clearance < 50 mL/min measured or calculated by Cockroft-Gault equation or GFR < 50 mL/min/1.73 m2 as calculated using modification of diet in renal disease (MDRD).<br>7. Significant, concurrent, uncontrolled medical condition including, but not limited to, renal, hepatic, hematological, gastrointestinal, endocrine, pulmonary, cardiac, neurological, cerebral, or psychiatric disease.<br>8. Concurrent anticancer therapy (eg, chemotherapy, radiation therapy, surgery, immunotherapy, biologic therapy, hormonal therapy, or tumor embolization).<br>9. Concurrent therapy with a potent CYP3A4 inducer or inhibitor. Subjects may enter screening when therapy with the potent inhibitor or inducer is completed and may begin study treatment after 1 week or 5 half-lives, whichever is longer.<br>10. Subjects who participated in any other study in which receipt of an investigational study drug occurred within 28 days before first dose of study treatment.<br>11. Current or previous other malignancy within 2 years of study entry, except cured basal or squamous cell skin cancer, superficial bladder cancer, prostate intraepithelial neoplasm, carcinoma in situ of the cervix, or other noninvasive malignancy.<br>12. Known HIV infection, or HBV or HCV viremia or at risk for HBV reactivation. HBV DNA and HCV RNA must be undetectable. At risk for HBV reactivation is defined as HBSAg positive or anti-HBc antibody positive.<br>13. Pregnant or actively breastfeeding women.<br>14. Unwilling to be transfused with blood components.<br>15. Known hypersensitivity to any of the active substances or any of their excipients, including a JAK inhibitor or docetaxel.<br>